Diplomat Pharmacy, Inc. (DPLO) Shares Bought by State Street Corp

State Street Corp grew its position in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) by 1.7% during the second quarter, according to its most recent filing with the SEC. The firm owned 1,265,089 shares of the company’s stock after acquiring an additional 20,834 shares during the period. State Street Corp owned about 1.86% of Diplomat Pharmacy worth $18,718,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. Louisiana State Employees Retirement System grew its holdings in shares of Diplomat Pharmacy by 0.6% during the 2nd quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the company’s stock worth $263,000 after acquiring an additional 100 shares during the period. Capstone Asset Management Co. grew its holdings in shares of Diplomat Pharmacy by 0.5% during the 2nd quarter. Capstone Asset Management Co. now owns 24,430 shares of the company’s stock worth $362,000 after acquiring an additional 120 shares during the period. Arizona State Retirement System grew its holdings in shares of Diplomat Pharmacy by 0.9% during the 2nd quarter. Arizona State Retirement System now owns 22,800 shares of the company’s stock worth $337,000 after acquiring an additional 200 shares during the period. Bank of Montreal Can grew its holdings in shares of Diplomat Pharmacy by 3.0% during the 2nd quarter. Bank of Montreal Can now owns 11,600 shares of the company’s stock worth $172,000 after acquiring an additional 340 shares during the period. Finally, Texas Permanent School Fund grew its holdings in shares of Diplomat Pharmacy by 1.5% during the 2nd quarter. Texas Permanent School Fund now owns 31,890 shares of the company’s stock worth $472,000 after acquiring an additional 470 shares during the period. Hedge funds and other institutional investors own 66.51% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://sportsperspectives.com/2017/11/19/diplomat-pharmacy-inc-dplo-shares-bought-by-state-street-corp.html.

DPLO has been the topic of a number of research analyst reports. BidaskClub downgraded Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 17th. Needham & Company LLC reiterated a “buy” rating and set a $23.75 target price (up previously from $19.75) on shares of Diplomat Pharmacy in a report on Wednesday, October 4th. Robert W. Baird restated a “buy” rating and issued a $20.00 price target on shares of Diplomat Pharmacy in a research note on Sunday, September 17th. TheStreet upgraded Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research note on Thursday, August 10th. Finally, Zacks Investment Research upgraded Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $19.39.

Shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) opened at $15.00 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. The firm has a market capitalization of $1,033.09, a P/E ratio of 19.48, a P/E/G ratio of 2.70 and a beta of 0.74. Diplomat Pharmacy, Inc. has a 52 week low of $12.25 and a 52 week high of $21.99.

Diplomat Pharmacy (NYSE:DPLO) last posted its quarterly earnings results on Monday, November 6th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.10. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The firm’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.21 EPS. analysts forecast that Diplomat Pharmacy, Inc. will post 0.85 earnings per share for the current fiscal year.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Want to see what other hedge funds are holding DPLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Diplomat Pharmacy, Inc. (NYSE:DPLO).

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply